Lupin Pharmaceuticals, Inc., the U.S. based wholly-owned subsidiary of Lupin Limited (Lupin), announced today that the U.S. Food and Drug Administration (FDA) has accepted their supplemental New Drug Application (sNDA) for Solosec® (secnidazole) for the treatment of trichomoniasis in adults and adolescents.
Medigen Vaccine Biologics (MVC) has collaborated with BlueWillow Biologics for the development of intranasal vaccine for SARS-CoV-2, the novel coronavirus responsible for Covid-19 disease.
Pharmaron Beijing, a fully integrated contract research and manufacturing organization offering laboratory, CMC and clinical development services for the life science industry, announced today that it has acquired 100% of the equity of Absorption Systems for up to $137.5m in cash.
Merck has agreed to acquire US-based clinical-stage biopharmaceutical company VelosBio for $2.75bn in cash.
ACG, a provider of integrated pharmaceutical manufacturing solutions, has purchased a significant stake in India-based contract research organisation (CRO) IQGEN-X.
The Coalition for Epidemic Preparedness Innovations (CEPI) has agreed to provide up to $328m to Clover Biopharmaceuticals for the development of Covid-19 vaccine candidate.
Sanofi and Kiadis, a clinical-stage biopharmaceutical company developing innovative ‘off the shelf’ natural killer (NK) cell based medicines for the treatment of life-threatening diseases, entered into a definitive agreement under which Sanofi will make a public offer (subject to satisfaction of certain customary conditions) to acquire the entire share capital of Kiadis for EUR 5.45 per share, representing an aggregate adjusted equity value of €308m.
US-based PerkinElmer has agreed to acquire UK-based cell engineering company Horizon Discovery Group in a deal valued at around $383m.
Swiss pharmaceutical company Novartis has acquired gene therapy company Vedere Bio in a deal valued at around $280m.
Machine-learning driven drug discovery and development company insitro has entered into a five-year collaboration with Bristol Myers Squibb to develop treatments for neurodegenerative disorders.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.